News & Updates

Show Multimedia Only

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

A recent study suggests that time-restricted eating (TRE) may help reduce weight and improve cardiometabolic health by regulating gut microbiota and serum metabolites.

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

In patients with stable inflammatory bowel disease (IBD) receiving advanced therapies who have comorbid obesity and/or diabetes, adjunctive treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide or tirzepatide does not appear to improve clinical outcomes, according to new research.

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

SGLT2i helps prevent cardiovascular events in diabetes patients with acute MI

30 Jun 2026

Early treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i) is associated with a lower cardiovascular risk among diabetes patients with acute myocardial infarction (MI), reports a study.

SGLT2i helps prevent cardiovascular events in diabetes patients with acute MI

30 Jun 2026

Inflammatory arthritis patients with overweight, obesity at high risk of COVID-19

29 Jun 2026 by

Among patients with inflammatory arthritis receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs, those with overweight or obesity face an increased risk of COVID-19 infection, according to a study from Singapore.

Inflammatory arthritis patients with overweight, obesity at high risk of COVID-19

29 Jun 2026

Elevated baseline LH, prior ADT predict poor response to clomiphene citrate

29 Jun 2026

Higher luteinizing hormone (LH) at baseline and a history of prior androgen-deprivation therapy (ADT) are associated with worse response to clomiphene citrate (CC) therapy in men with low testosterone, a study has shown.

Elevated baseline LH, prior ADT predict poor response to clomiphene citrate

29 Jun 2026

Lifestyle intervention enough to reduce multimorbidity risk in adults with prediabetes

28 Jun 2026

In adults with prediabetes, lifestyle interventions may help reduce the development of chronic conditions, according to a study.

Lifestyle intervention enough to reduce multimorbidity risk in adults with prediabetes

28 Jun 2026

Orforglipron promotes weight loss across all menopausal stages

27 Jun 2026 by

Once-daily treatment with the highest orforglipron dose is associated with significant reductions in body weight and waist circumference at week 72 in women with obesity or overweight, regardless of menopausal status, according to a post hoc analysis of the phase III ATTAIN-1 and -2 trials presented at ADA 2026.

Orforglipron promotes weight loss across all menopausal stages

27 Jun 2026

Novel GLP-1 RA for weight management clears phase 2 study

26 Jun 2026

The investigational oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron yields meaningful weight reductions with a safety profile consistent with the drug class, according to a phase 2 dose-ranging study.

Novel GLP-1 RA for weight management clears phase 2 study

26 Jun 2026

Novel petrelintide shows promise for obesity treatment

25 Jun 2026 by

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

Novel petrelintide shows promise for obesity treatment

25 Jun 2026

Berobenatide a promising addition to the current GLP-1 RA roster

24 Jun 2026 by

In the phase II VESPER-2 trial, the investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) berobenatide shows robust reductions in weight and HbA1c in adults with obesity/overweight and type 2 diabetes (T2D).

Berobenatide a promising addition to the current GLP-1 RA roster

24 Jun 2026

News & Updates

Showing Endocrinology articles

Showing

Specialty:

Time-restricted eating reshapes gut microbiota to induce weight loss

Time-restricted eating reshapes gut microbiota to induce weight loss

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

SGLT2i helps prevent cardiovascular events in diabetes patients with acute MI

SGLT2i helps prevent cardiovascular events in diabetes patients with acute MI

Inflammatory arthritis patients with overweight, obesity at high risk of COVID-19

Inflammatory arthritis patients with overweight, obesity at high risk of COVID-19

Elevated baseline LH, prior ADT predict poor response to clomiphene citrate

Elevated baseline LH, prior ADT predict poor response to clomiphene citrate

Lifestyle intervention enough to reduce multimorbidity risk in adults with prediabetes

Lifestyle intervention enough to reduce multimorbidity risk in adults with prediabetes

Orforglipron promotes weight loss across all menopausal stages

Orforglipron promotes weight loss across all menopausal stages

Novel GLP-1 RA for weight management clears phase 2 study

Novel GLP-1 RA for weight management clears phase 2 study

Novel petrelintide shows promise for obesity treatment

Novel petrelintide shows promise for obesity treatment

Berobenatide a promising addition to the current GLP-1 RA roster

Berobenatide a promising addition to the current GLP-1 RA roster